首页> 外文期刊>The Lancet >Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
【24h】

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

机译:奥沙利铂,氟尿嘧啶和亚叶酸长期治疗转移性大肠癌的随机多中心试验。国际癌症慢性疗法组织。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The efficacy of chemotherapy may be affected by circadian rhythms. Therefore, we tested chronomodulated infusion (administered to coincide with relevant circadian rhythms) of oxaliplatin, fluorouracil, and folinic acid compared with a constant-rate infusion method. The combination of three drugs was delivered for 5-day courses with 16-day intervals. METHODS: We expected chronotherapy to increase objective response rate by 20% compared with constant-rate infusion. We tested this effect in a randomised multicentre trial involving patients with previously untreated metastases from colorectal cancer who were enrolled at nine institutions in three countries. 93 patients were assigned chronotherapy and 93 were assigned constant-rate infusion via multichannel programmable ambulatory pumps. The trial was interrupted when a significant difference in main outcome was reached. All data were analysed by intention to treat. FINDINGS: On enrollment, we found significant imbalances in two characteristics-abdominal gland or bone metastases (constant-rate infusion two patients, chronotherapy ten patients) and relapse from surgically treated metastases (constant-rate infusion seven patients, chronotherapy 22 patients). An objective response was obtained in 47 (51%) of the chronotherapy group, and in 27 (29%) of the constant-rate group (difference 21.5% [95% CI 13.7-31.2], p = 0.003). Chronotherapy reduced five-fold the rate of severe mucosal toxicity (14% vs 76%, p < 0.0001) and halved that of functional impairment from peripheral sensitive neuropathy (16% vs 31%, difference 15.0% [9.5-25.7], p < 0.01). Median time to treatment failure was 6.4 months on chronotherapy and 4.9 months on constant-rate infusion (p = 0.006), and 24% of the patients from the constant-rate infusion group received chronotherapy after failure. With a minimum follow-up of 3 years, median survival times and 3-year survival were similar in both groups (15.9 vs 16.9 months and 22% vs 21%, respectively). INTERPRETATION: Chronotherapy was significantly less toxic and more effective than constant-rate infusion. The results support the concept of temporal selectivity of cancer chemotherapy.
机译:背景:昼夜节律可能会影响化疗的疗效。因此,与恒速输注方法相比,我们测试了奥沙利铂,氟尿嘧啶和亚叶酸的定时输注(与相关的昼夜节律相一致)。三种药物的组合以16天为间隔的5天疗程。方法:我们希望与恒定速率输注相比,计时疗法可将客观缓解率提高20%。我们在一项随机多中心试验中对该效果进行了测试,该试验涉及三个国家中九家机构的先前未接受过治疗的大肠癌转移患者。通过多通道可编程门诊泵对93例患者进行了时间疗法,并对93例进行了恒速输液。当主要结局达到显着差异时,试验被中断。所有数据均按意向分析。结果:在入组时,我们发现两个特征显着失衡-腹腺或骨转移(恒速输注2例,经时疗法10例)和经手术治疗的转移复发(恒速输注7例,经时疗法22例)。计时治疗组中有47名(51%)和恒速治疗组中有27名(29%)获得了客观反应(差异为21.5%[95%CI 13.7-31.2],p = 0.003)。慢性疗法使严重粘膜毒性的发生率降低了五倍(14%比76%,p <0.0001),而外周敏感神经病引起的功能障碍的比例降低了一半(16%比31%,相差15.0%[9.5-25.7],p < 0.01)。计时疗法中,治疗失败的中位时间为6.4个月,恒速输注中为4.9个月(p = 0.006),恒速输液组中有24%的患者在失败后接受了计时疗法。至少随访3年,两组的中位生存时间和3年生存率相似(分别为15.9个月和16.9个月,以及22%对21%)。解释:与恒速输注相比,长期疗法的毒性明显更低,更有效。结果支持癌症化学疗法的时间选择性的概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号